What is Zacks Research’s Forecast for BIO FY2028 Earnings?

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Investment analysts at Zacks Research issued their FY2028 earnings estimates for Bio-Rad Laboratories in a research report issued on Monday, March 2nd. Zacks Research analyst Team expects that the medical research company will post earnings per share of $9.87 for the year. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.81 per share.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Thursday, February 12th. The medical research company reported $2.51 earnings per share for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.06). Bio-Rad Laboratories had a net margin of 29.42% and a return on equity of 3.86%. The company had revenue of $693.20 million during the quarter, compared to analysts’ expectations of $694.64 million. During the same period in the prior year, the business posted $2.90 earnings per share. The company’s quarterly revenue was up 3.9% compared to the same quarter last year.

Several other brokerages have also recently commented on BIO. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research report on Monday, December 29th. Wall Street Zen lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Bio-Rad Laboratories has a consensus rating of “Hold” and a consensus target price of $358.50.

Bio-Rad Laboratories Price Performance

Shares of Bio-Rad Laboratories stock opened at $284.83 on Wednesday. The stock has a market capitalization of $7.69 billion, a P/E ratio of 10.21 and a beta of 1.18. The business has a 50 day simple moving average of $296.91 and a two-hundred day simple moving average of $301.34. Bio-Rad Laboratories has a 12 month low of $211.43 and a 12 month high of $343.12. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.62 and a quick ratio of 4.19.

Institutional Investors Weigh In On Bio-Rad Laboratories

A number of hedge funds have recently modified their holdings of the company. Quent Capital LLC purchased a new position in Bio-Rad Laboratories during the third quarter worth about $25,000. Farther Finance Advisors LLC raised its position in shares of Bio-Rad Laboratories by 52.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company’s stock valued at $29,000 after buying an additional 36 shares during the period. Danske Bank A S purchased a new stake in shares of Bio-Rad Laboratories during the 4th quarter valued at approximately $30,000. Geneos Wealth Management Inc. lifted its holdings in Bio-Rad Laboratories by 115.2% in the second quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 76 shares during the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in Bio-Rad Laboratories in the fourth quarter worth approximately $47,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Trending Headlines about Bio-Rad Laboratories

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Zacks raised its Q1 2027 EPS forecast to $2.22 (from $2.12), a modest upward revision that could be read as a small near-term beat to expectations for that quarter.
• Neutral Sentiment: Zacks published an initial FY2028 EPS estimate of $9.87. As an early/forward-year projection this is informative but carries uncertainty and is not directly comparable to current-year consensus figures.
• Negative Sentiment: Zacks cut a string of near‑ and medium‑term EPS forecasts — small trims to Q1 2026 ($2.77), Q2 2026 ($2.34), Q4 2026 ($2.59) and FY2026 (to $10.32 from $10.36), and larger cuts to FY2027 (to $9.30 from $9.38) and several Q2–Q3 2027 quarters — signaling a weaker earnings trajectory than previously modeled. These downward revisions, taken together, are the main negative catalyst from this batch of research notes because they lower forward earnings expectations and could pressure valuation multiples.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.